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Abstract
The complement system is involved in the defence against bacterial infection, or in the elimination of tumour cells.
However, disturbances in this system contributes to the pathogenesis of various inflammatory diseases. The efficiency of
therapeutic anti-tumour antibodies is enhanced when the complement system is stimulated. In contrast, cancer cells are
able to inhibit the complement system and thus proliferate. Some marine molecules are currently being developed as new
drugs for use in humans. Among them, known exopolyssacharides (EPSs) generally originate from fungi, but few studies
have been performed on bacterial EPSs and even fewer on EPSs extracted from deep-sea hydrothermal vent microbes. For
use in humans, these high molecular weight EPSs must be depolymerised. Furthermore, the over-sulphation of EPSs can
modify their biological activity. The aim of this study was to investigate the immunodulation of the complement system by
either native or over-sulphated low molecular weight EPSs isolated from vent bacteria in order to find pro or anti-activators
of complement.
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Introduction
The complement system plays a very important role in the
defence against infection, in antibody activity and in the clearance
of antigen-antibody complexes from the bloodstream [1–3]. Its
perpetual activation leads to inflammatory diseases creating
irreversible tissue damages [4]. The complement system consists
of approximately 35 different serum and cellular proteins,
including positive and negative regulators that interact in a
cascade. For example, many of the first components acting in the
cascade are serine proteases that sequentially activate one another
[5–7]. The complement system can be activated through three
pathways: the classical, alternative and mannose-binding lectin
(MBL) pathways. The classical pathway occurs mainly when a
complex antigens and IgG (or IgM) antibodies binds to the first
complement component C1q [8]. The alternative, or properdin,
pathway is induced through contact with activated C3 that is
deposited on a variety of surfaces, including pathogens such as
viruses and fungi, but also on host cells in a variety of diseases such
as auto-immune disorders or psoriasis [5,9]. The MBL pathway
initiates complement activation when notably lectins recognise
mannose on the cell surface of pathogens such as bacteria [10].
Once activated, a cascade of events occurs until all three pathways
converge at C3, ultimately leading to the assembly of a multi-
protein complex (C5b6789) on a cell membrane. This is known as
the membrane attack complex (MAC), and results in cell lysis.
Among the key mechanisms and molecules involved in the innate
immune response, glycosylation and glycans play essential roles in
receptor recognition of ligands. Oligosaccharides interact with
proteins of the complement system and play a major role in the
stability, recognition and regulation of these proteins [11,12].
Microorganisms can be considered as a renewable source and
can be efficient producers of a large variety of bioactive molecules
such as metabolites, proteins, peptides and novel exopolysacchar-
ides (EPSs) [13]. Most bacterial EPSs have very complex and
diverse structures that confer numerous functional properties.
Over the past several years, there has been growing interest in the
biological activity of microbial exopolysaccharides in regard to
their anti-tumour activity [14–16], immunostimulatory activity
[17–19], as well as their role in bone and tissue regeneration
[20,21] and anti-complementary activity [22].
In the present study, we evaluated the potential activity of two
marine bacterial EPSs on the complement system. The first EPS,
called GY785, is a high molecular weight (up to 106 Da),
branched, sulphated polysaccharide produced by Alteromonas
infernus, a marine bacterium isolated from a deep-sea hydrothermal
vent [23]. The second EPS, called HE800, is produced by Vibrio
diabolicus another marine bacterium isolated from a deep-sea
hydrothermal vent [24]; it has a linear backbone and a molecular
mass of about 8?105 Da. The latter EPS can be classified as a
glycosaminoglycan due to some structural similarity with hya-
luronic acid. This biopolymer has already shown very interesting
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biological properties in regard to bone and skin regeneration
[20,21]. The high molecular weight polymers were first depoly-
merised to decrease their viscosity, and to enhance their
interaction with potential receptors or ligands. Furthermore,
sulphation of the hydroxyl groups present on the polysaccharides
can substantially modify their biological activity [25]. Thus, we
assessed the effect of over-sulphated, low molecular weight (LMW)
EPSs on the complement system. Interaction between the
modified EPSs and the C1q protein of the complement system
was studied and the results are reported and discussed.
Material and Methods
2.1. Production, purification and characterization of
native EPSs
The isolation, characteristics, production and purification of the
GY785 and HE800 EPSs have been previously described [23,24].
Briefly, exopolymer production was performed at 25uC in a 2-L
fermenter (SGI-Inceltech, Toulouse, France) containing 1 liter of
2216E-glucose broth. Batch was inoculated at 10% (v/v) with a
suspension of cells in exponential phase. The pH was adjusted and
maintained at 7.2 by automatic addition of a 0.25 mol L21 sodium
hydroxide solution. The air flow was fixed at 30 L h21 and the
agitation rate from 200 to 1100 rev min21. Bacterial growth was
determined by measuring the culture turbidity at 520 nm. After
60 h of fermentation, bacterial cells were removed from the
culture medium by centrifugation (15,000g, 80 min). The super-
natant containing the excreted EPS was then purified by filtration
through a cellulose membrane (0.7 mm) and then by ultrafiltration
(100 kDa) before being freeze-dried and stored at room temper-
ature away from light and moisture.
The monosaccharide residues of this both EPSs were analysed
after acid methanolysis of the polymer and subsequent GC
analyses as trimethylsilyl derivatives [26,27]. The protein content
was determined using Lowry method [28] with bovine serum
albumin used as a standard. The sulphate content was determined
by Fourier-transform infrared analysis [29]. Elemental analysis (C,
H, N and S) was performed by the Central Microanalysis
Department of the CNRS (Gif-sur-Yvette, France).
2.2. Depolymerisation of the EPSs
The EPSs were hydrolysed using radical depolymerisation, a
procedure adapted from Nardella et al. [30]. Briefly, 400 mg of
EPSs were dissolved in water (100 mL) and copper acetate was
added (0.18 mM of Cu2OAc4). The temperature was maintained
at 60 uC. A 0.14% (w/v) H2O2 aqueous solution was then added
at a flow rate of 1 mL/min. The reaction pH was maintained at
pH 7 by continuous addition of 10 N sodium hydroxide. The
reaction was stopped after 2 h and the EPSs were reduced by
NaBH4 (1/1, w/w). The excess of NaBH4 was eliminated by
adding acetic acid. The precipitate formed was first filtered with a
Bu¨chner system using 3 mm microfiber filters. The residual copper
was then eliminated on a Chelex 100 resin using water as an eluent
(Bio-Rad, Hercules, CA, USA). The solution (called DR) was
concentrated, desalinated by ultrafiltration with a 1 kDa cut-off
membrane (Millipore, Molsheim, France) and then freeze-dried.
2.3. Sulphation of the LMW EPSs
The resulting depolymerised EPSs were chemically over-
sulphated (called DROS) as previously described [31] with some
modifications. Briefly, 1 g of dried LMW EPS was dissolved in
50 mL of double-distilled water and then applied to a cation
exchange column (1620 cm) of Amberlite IR 120H+ (Fluka
Chemica, Saint-Quentin-Fallavier, France) equilibrated with
double-distilled water. The column was then washed with water
and the EPS fraction was collected, neutralised with a triethyl-
amine solution to pH 5.5–6 and freeze-dried. The product was
then dissolved in 100 mL of N,N,dimethylformamide (DMF)
(Sigma-Aldrich) and mixed slowly for 2 h at room temperature
then for another 2 h at 45 uC. An excess of pyridine-SO3 complex
(5/1 (w/w) pyridine/EPS) was added and the reaction took place
for 2 h at 45 uC. The reaction was stopped by the addition of an
equal volume of ice-cold water. Finally, the solution was
neutralised to pH 7.5 with a 2 M NaOH solution, concentrated,
desalinated by ultrafiltration with a 1 kDa cut-off membrane
(Millipore) and then freeze-dried.
2.4. Molecular weight determination of depolymerised
EPSs
Each LMW EPS (2 mg/mL) was analysed by high-pressure size
exclusion chromatography in 0.1 M ammonium acetate at a flow
rate of 0.5 mL/min using a Superdex 200 column (Amersham,
Saclay, France). Calibration was performed using pullulan
standards [13], which are neutral glycans. Calculations of Mw
(weight-average molecular mass), Mn (number-average molecular
mass) and Ip (polydispersity index) were carried out using Aramis
software (JMBS De´veloppements, Le Fontanil, France).
2.5. Capacity of NHS (normal human serum) to lyse 50%
of EA through the classical pathway (CH50 assay)
CH50, represents the NHS concentration that leads to lysis of
50% of antibody-sensitised sheep erythrocytes (EA). To determine
the CH50 concentration, 800 mL of NHS, at different concentra-
tions in VBS2+ [(4 mM veronal, 0.15 mM NaCl, 0.15 mM Ca2+,
0.5 mM Mg2+ (Sigma-Aldrich), pH 7.3] was incubated with
200 mL of EA at 108 cells/mL for 45 min at 37 uC. EA were
prepared by incubating sheep erythrocytes with rabbit anti-sheep
erythrocyte antibodies (bioMe´rieux, Paris, France) as described by
Kazatchkine [32]. Controls with 0% (L0) and 100% (L100) of lysis
were obtained by incubating, in the same conditions, 800 mL of
VBS2+ with 200 mL EA. After dilution in 2 mL of cold 0.15 M
NaCl (except for L100, where 2 mL of double-distilled water
(ddH2O) were added) and centrifugation, the residual released
haemoglobin in the supernatant was determined by measuring the
optical density (OD) at 414 nm [32].
2.6. Evaluation of the classical complement pathway
activation
The ability of the LMW EPSs to activate the classical pathway
of the complement system was measured using haemolytic assays
in two steps (cf, above schema). First, various amounts of LMW
EPSs (0 to 100 mg) were pre-incubated with 15 mL of NHS (at
CH50 in VBS
2+) for 45 min at 37 uC. If they can activate
complement, consumption of complement molecules occurred. In
the second step, a mixture of 100 mL of C1q, C4 or C2 deficient or
depleted sera (Sigma-Aldrich, Paris, France) (1/40 (v/v) in VBS2+)
and 100 mL of EA at 108 cells/mL were added and incubated for
another 45 min at 37 uC. If no lysis of EA was observed, this
indicated that activation of complement was achieved previously;
the percentage of EA lysis inhibition corresponding to the
percentage of activation. The controls L0 and L100 were obtained
as described above. After dilution with 2 mL of cold 0.15 M NaCl
and centrifugation, the amount of haemoglobin released was
assessed by measuring the OD (Optical Density) of supernatants at
414 nm. A positive control of the reaction was obtained by
incubating aggregated IgG (0–100 mg) in the same experimental
conditions [33]. Results were presented as percentage of activation
Modulation of Complement Activity by EPS
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corresponding to percentage of EA lysis inhibition, then the
percentage of consumption of complement molecules by EPSs in
CH50 NHS.
2.7. Evaluation of the inhibited-complementary activity
of depolymerized EPSs
The inhibited complement activation of the depolymerised and
over-sulphated LMW EPS was assessed using haemolytic assays.
The ability of NHS to lyse EA through the classical pathway was
assessed with various amounts of LMW EPSs. In this process,
350 mL of NHS (1/100 in VBS2+) were incubated with 450 mL of
VBS2+ buffer containing 0–10 mg of LMW EPS and 200 mL of EA
at 108 cells/mL, for 45 min at 37uC. After addition of 2 mL of
0.15 M NaCl and centrifugation, the residual CH50 units of the
supernatant were determined by the measuring the OD at
414 nm. Positive control of the reaction was obtained by
incubating 0–10 mg of a LMW sulphated fucoidan (called FTDR)
in the same experimental conditions. The Figure 1 resumes the
evaluation of the classical complement pathway activation or
inhibition.
2.8. Surface plasmon resonance (SPR) analysis
C1q was immobilized on a CMD 200 l sensor chip (Xantec,
Duesseldorf, Germany) in PBS buffer (running buffer) via its
primary amino groups using a standard EDC/NHS-mediated
amine coupling procedure. In this procedure, 100 mL of various
dilutions of GY 785 DROS in PBS buffer (running buffer) were
injected at a flow rate of 100 mL/min. The sensor surface was
regenerated by injection of 10 mM NaOH in 2 M NaCl. The
response was monitored over time (sensorgram) at 25uC. All
sensorgrams were processed using a double referencing method
[34]. First, the responses from the control cell were subtracted
from the binding responses collected over the reaction cell to
correct for bulk refractive index changes. Second, the response
from the blank injection was subtracted to remove responses
observed due to the change in running buffer and other system
artefacts. The sensorgrams obtained were fitted using a 1:1
interaction model with drifting baseline, using the Biacore
evaluation sofware (version 3.2).
2.9. Statistical analysis
All results are expressed as means 6 standard error. Statistical
differences between experimental groups were determined by
analysis of variance (ANOVA) and individual means were
compared with a Student’s t-test using InStat (GraphPad Software,
San Diego, CA, USA). Values of p,0.05 were considered
statistically significant.
Results and Discussion
3.1. Production of LMW EPSs
Classical depolymerisation methods include chemical hydroly-
sis, ozonolysis, oxidation or specific enzymatic depolymerisation.
An alternative method, radical depolymerisation, generally pre-
serves the structure of the repetition unit of an EPS. In radical
depolymerisation, free radicals are formed via the hydrogen
peroxide-cupric redox system, leading to good yield under mild
experimental conditions [13,26]. The molecular weights of the
depolymerised EPSs are listed in Table 1. Results are expressed in
equivalent pullulans, used as the calibration standard. Gas
chromatography (GC) analysis of monosaccharides as per-O-
trimethylsilyl methylglycosides and the determination of mono-
saccharide molar ratios were carried out, demonstrating that the
monosaccharide composition was similar before and after
depolymerisation. For GY785, the monosaccharide ratio was
found to be 4:2:1:2 glucose:galactose:galacturonic acid:glucuronic
acid and for HE800, the composition was 1:1:2 N-acetyl
glucosamine:N-acetyl galactosamine:glucuronic acid. Depolymer-
isation did not alter the osidic composition of either EPS. The
LMW EPS fractions had the same sulphate-to-total sugar ratios as
the high molecular weight EPSs. The percentage of proteins
present with the EPS was determined using the Lowry colorimetric
assay. Depolymerisation eliminated most of the proteins.
3.2. Sulphation of LMW EPSs GY785 and HE800
The over-sulphated molecules, designated HE800 DROS and
GY785 DROS, were analysed for their chemical composition, and
the sulphate content was estimated using Fourier-transform
infrared analysis and elemental analysis and compared to the
native EPS and LMW forms. Both methods gave the same, results,
as shown in Table 1. GY785 DR and the GY785 DROS showed
sulphate contents of 10% and 42%, respectively, whereas the
sulphate content of HE800 DROS was 34% (w/w). Gas
chromatography analysis of monosaccharides as per-O-trimethylsi-
lyl methylglycosides, carried out after over-sulphation, showed that
over-sulphation did not modify the osidic composition of either
EPS.
3.3. Complement activation properties of the LMW EPSs
As glycosylation can influence complement activity, the classical
pathway of complement system was activated via contact with
NHS, used as the complement source, with EA, leading to the lysis
of the EA.
To assess the ability of the GY785 DR and HE800 DR to
activate the complement system in NHS, we assessed how
occurred complement activity of serum deficient or depleted in
proteins C1q, C2 and C4 of the complement system. First, the
CH50, representing the NHS dilution that leads to lysis of 50% of
the EA, was determined. In our experiments, the CH50 was
reached for a 1:100 dilution of NHS. Then, increasing amounts of
LMW EPS (0-100 mg) in NHS solution at the CH50 concentration
were incubated with deficient or depleted serum and complement
activation was determined. In all experiments (Figure 2), aggre-
gated IgG were used as a positive control, demonstrating an ability
to activate the complement system, reaching 70% activation for
100 mg of proteins.
Our results demonstrate that HE800 DR and GY785 DR
activated the classical complement system (Figure 2A), HE800 DR
in more important way. These results were confirmed in Figures 2B
Figure 1. Evaluation of the classical complement pathway
activation or inhibition.
doi:10.1371/journal.pone.0094965.g001
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and 2C. In fact, for GY785 DR the plateau was reached at 38%
activation for a dose of 100 mg (Figure 2B). As shown in Figure 2C,
the amount of activation of the complement system in the presence
of HE800 DR in veronal buffer (VBS2+) increased rapidly with the
amount of polysaccharide and reached a plateau that correspond-
ed to 60% activation for 50 mg of HE800 DR. We can note that
results obtained for GY785 DR in three different sera were
homogenous this was not the case for HE800 DR. In fact, for C4
deficient serum, complement activation was lower. Different
explanations could be suggested such as conformation of EPSs
and its fixation on complement molecule but must to be explored
more precisely. As mentioned above, various glycans have been
described to activate the classical pathway of the complement
system [35]. For example, hyperacute rejection in pig-to-primate
xenotransplantation is due to a carbohydrate antigen, called the
Gal-a1,3)Gal oligosaccharide, and humans are predisposed to
produce large amounts of a natural antibody called ‘anti-Gal’,
which binds specifically to a-Gal epitopes on glycolipids and
glycoproteins [36,37] followed by activation of the complement
system [38]. Based on these observations, we have previously
Table 1. Molecular weights (Mw), polydispersity index (Ip), yield of sulphate groups and percentage of proteins in native,
depolymerized (DR) and over-sulphated (DROS) GY785 and HE800 EPSs, using pullulans as standards.
Mw (Da) Mn (Da) Ip (Mw/Mn) Sulphates(1) % w/w Sulphates(2) % w/w Proteins (%)
Native GY785 1.4?106 1.2?106 1.2 10 9 13
GY785 DR 1.7?104 6.0?103 2.8 10 8 ,1
GY785 DROS 2.3?104 8.8?103 2.7 42 37 ,1
Native HE800 7.4?105 6.7?105 1.1 0 0 1
HE800 DR 2.9?103 1.3?104 2.2 0 0 ,1
HE800 DROS 2.7?104 1.9?104 1.4 34 29 ,1
Mw, weight-average molecular mass; Mn, number-average molecular mass; sulphates(1): percentage of sulphate groups determined using Fourier-transform infrared
analysis; sulphates(2): percentage of sulphate groups determined using elemental analysis.
doi:10.1371/journal.pone.0094965.t001
Figure 2. Activation of the classical complement pathway by depolymerised GY785 and HE800. Activation was measured by the
capacity of normal human serum (NHS) incubated with various amounts of GY785 DR or HE800 DR, to restore the haemolytic activity of serum
deficient in complement proteins C1q (A), C4 (B) and C2 (C). Aggregated IgG were used to validate the experimental model using C2-deficient serum.
Each point represents the mean (SEM) from 3 to 6 determinations.
doi:10.1371/journal.pone.0094965.g002
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shown that when the Gal-a1,3)Gal oligosaccharide is coupled to a
therapeutic antibody, there is an increase in its efficacy [38]. ABO-
incompatible blood transfusion shares several similarities with
hyperacute rejection in xenotransplantation [39]. Lipopolysaccha-
rides can also activate the complement system by directly
recruiting the C1q protein [40]. This study is the first report of
a correlation between a marine bacterial exopolysaccharide and
direct complement activation, involving in particular HE 800 DR,
whose structure has some similarities with hyaluronic acid. More
studies must be carried out to determine precisely how this
polysaccharide activate the complement system, particularly in its
interaction with the C1q protein.
3.4. Complement inhibition properties of sulphated LMW
EPSs
Sulphated glycosaminoglycans [41] are well known to inhibit
the complement system in vitro. We investigated the role of the
sulphate groups on the EPS glycan structure in regard to their
capacity to inhibit the complement system, particularly via the
classical pathway. Over-sulphated LMW EPS (GY785 DROS and
HE800 DROS) showed inhibited complement activation as
indicated by a decrease in EA lysis (Figures 3A and 3B). The
inhibition activity was compared to that of an LMW fucoidan
(FTDR) extracted from the brown alga Ascophyllum nodosum [42]
and used as a positive control in the experiment. This LMW
polysaccharide is naturally sulphated (35% (w/w) sulphate
content) with a molecular weight of 1.8?104 Da. It has already
been described to have complement inhibiting activity in the same
experimental conditions [42,43].
More specifically, we found that GY785 DROS inhibited, in a
dose-dependent manner, the classical pathway of the complement
system (Figure 3A). This capacity increased very rapidly with small
amounts of polymer and reached a plateau corresponding to 78%
inhibition for a quantity of 10 mg of GY785 DROS compared to
41% with the same quantity of FTDR. The capacity to inhibit
50% of the complement system was obtained using 750 ng of
GY785 DROS. GY785 DROS thus inhibits the complement
system more efficiently than FTDR does, particularly at low
concentrations. Furthermore, we found that HE800 DROS also
has complement inhibiting effect (Figure 3B), whereas the non-
sulphated LMW EPS had no effect on inhibition. HE800 DROS
inhibition of the complement system was similar to FTDR
inhibition activity, with an inhibition of 48% and 41% obtained
with 10 mg of HE800 DROS and FTDR, respectively. In addition,
the capacity to inhibit 50% of the complement system was
obtained using 2.5 and 3 mg of HE800 DROS and FTDR,
respectively.
Figure 3. Inhibition of complement activation in normal human serum by depolymerised GY785 DR, over-sulphated GY785 DROS
(A), depolymerised HE800 DR, over-sulphated HE800 DROS (B) and FTDR. Inhibition of the classical pathway was evaluated by measuring
antibody-sensitised sheep erythrocyte haemolysis. The amount of each polysaccharide is indicated for a 100-fold diluted NHS prior to addition of
erythrocytes. Each point represents the mean (shown with standard error bars) from four determinations, statistically analysed using Student’s t-test.
* indicates significant differences (p,0.05) between GY785 DROS and FTDR.
doi:10.1371/journal.pone.0094965.g003
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These results suggest that the capacity to inhibit the comple-
ment system depended mainly on the sulphate groups, but also on
polysaccharide structure (conformation, monosaccharide compo-
sition and physico-chemical properties).
3.5. Interaction of depolymerised and sulphated LMW
GY785 and HE800 with the C1q complement protein
As described above, activity of fucoidan is due to complement
inhibition via interaction with the C1q protein [42,44]. Other
studies have been performed on sulphated polysaccharides
showing interaction with C1q protein and resulting in inhibition
of complement system [45]. To demonstrate an interaction
between the over-sulphated polysaccharides and serum proteins,
it was not possible to characterise an interaction specifically with
C1q. To better understand the physical association of C1q with
GY785 DROS, we observed their interaction using surface
plasmon resonance (SPR). SPR measures biomolecular interac-
tions in real-time in a label-free environment, providing both
equilibrium and kinetic information on the formation of
complexes. SPR has been used to study the interactions between
various complement proteins [46]. However, SPR studies on
complement-protein interactions with sulphated polysaccharides
are very rare [47,48]. As complement inhibition was highest
observed with GY785 DROS, only the interaction between this
sulphated EPS with C1q was analysed by SPR. C1q was
immobilised via its unsubstituted amino groups. Dextran sulphate,
used as a negative control, did not interact with C1q (data not
shown), but a specific response was monitored with GY785 DROS
(Figure 4). The simultaneous fit of the association and dissociation
phases, using a 1:1 Langmuir model, allowed us to the determine a
binding affinity value (KD) of about 2 mM, indicating the
formation of a stable complex between GY785 DROS and the
C1q complement protein.
A glycosaminoglycan chondroitin 4-sulfate proteoglycan secret-
ed by human B lymphocytes has been proposed to act as a
physiological inhibitor of C1q through the inhibition of C1
assembly [45]. More recently, fucoidan (as for FTDR) has been
described to protect C1q from trypsin cleavage, indicating that
fucoidan binds C1q at two different sites, one in the globular
domain and the other in the stem, in the vicinity of the interaction
site with C1s-C1r-C1r-C1s. This interaction is also responsible for
the inhibition activity of fucoidan [44]. Based on these results, we
propose that the sulphate groups on polysaccharides confer the
ability to inhibit C1 by promoting an interaction with the C1q
protein via the same domain as that observed in fucoidan. This
protein-polysaccharide association probably involves ionic inter-
actions between positive residues of this domain and the sulphate
groups of the polysaccharide.
Conclusions
Biological products on complement activity were obtained from
new marine bacterial EPS originating from an extreme environ-
ment, following free radical depolymerisation and sulphation. A
novel activator of the complement system was discovered. We
demonstrated that sulphation of these polysaccharides confers
inhibition of complement activity, mainly for GY 785 DROS.
These data open very interesting perspectives for the treatment of
diseases caused by deregulation of the immune system and over-
activation of the complement system.
Figure 4. SPR sensorgrams of C1q-GY785 DROS interactions. Concentrations of GY785 DROS (from top to bottom) were 100, 50, 25, and
6.5 mM, respectively.
doi:10.1371/journal.pone.0094965.g004
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